Bg pattern

TRUSOPT 20 mg/ml EYE DROPS SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use TRUSOPT 20 mg/ml EYE DROPS SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

TRUSOPT 20 mg/ml eye drops, solution

dorzolamida

Read this package leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this package leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the package leaflet

  1. What is TRUSOPT and what is it used for
  2. What you need to know before you use TRUSOPT
  3. How to use TRUSOPT
  4. Possible side effects
  5. Storage of TRUSOPT
  6. Contents of the pack and further information

1. What is TRUSOPT and what is it used for

TRUSOPT contains dorzolamida, which belongs to a group of medicines called "carbonic anhydrase inhibitors".

This medicine is prescribed to lower high pressure in the eye and to treat glaucoma. This medicine may be used alone or in combination with other medicines that lower pressure in the eye (called beta-blockers).

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use TRUSOPT

Do not use TRUSOPT

  • if you are allergic to dorzolamida hydrochloride or any of the other ingredients of this medicine (listed in section 6).
  • if you have severe kidney problems or a history of kidney stones.

Warnings and precautions

Consult your doctor or pharmacist before you start using TRUSOPT.

Tell your doctor or pharmacist if you have or have had any medical problems, including eye problems and eye surgeries, and if you have any allergy to any medication.

If you experience any eye irritation or new eye disorder, such as redness of the eye or swelling of the eyelids, consult your doctor immediately.

If you suspect that TRUSOPT is causing an allergic reaction (for example, skin rash, severe skin reaction, or itching), stop using this medicine and consult your doctor immediately.

Children

TRUSOPT has been studied in infants and children under 6 years of age who had high pressure in the eye(s) or had been diagnosed with glaucoma. For more information, consult your doctor.

Older people

In studies with TRUSOPT, the effects of this medicine were similar in both older and younger patients.

Use in patients with liver impairment

Tell your doctor if you have or have had liver problems.

Using TRUSOPT with other medicines

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines (including eye drops). This is especially important if you are taking another carbonic anhydrase inhibitor such as acetazolamide, or a sulphonamide.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.

Pregnancy

Do not use this medicine during pregnancy. Tell your doctor if you are pregnant or planning to become pregnant.

Breastfeeding

If treatment with this medicine is required, breastfeeding is not recommended. Tell your doctor if you are breastfeeding or planning to breastfeed.

Driving and using machines

No studies on the effects on the ability to drive and use machines have been performed. There are side effects associated with TRUSOPT, such as dizziness and blurred vision, that may affect your ability to drive and/or operate machinery. Do not drive or operate machinery until you feel well or your vision is clear.

TRUSOPT contains benzalkonium chloride

This medicine contains approximately 0.002 mg of benzalkonium chloride in each drop, equivalent to 0.075 mg/ml.

Benzalkonium chloride may be absorbed by soft contact lenses, altering their colour. Remove contact lenses before using this medicine and wait 15 minutes before putting them back.

Benzalkonium chloride can cause eye irritation, especially if you have dry eyes or other corneal diseases (the transparent layer on the front of the eye). Consult your doctor if you feel any unusual sensation, itching, or pain in the eye after using this medicine.

3. How to use TRUSOPT

Follow exactly the instructions for administration of this medicine given by your doctor. If you are unsure, consult your doctor or pharmacist again. The appropriate dosage and duration of treatment will be determined by your doctor.

When this medicine is the only medicine used, the recommended dose is one drop in the affected eye(s) in the morning, afternoon, and evening.

If your doctor has recommended that you use this medicine with a beta-blocker eye drop to reduce eye pressure, the recommended dose is one drop of TRUSOPT in the affected eye(s) in the morning and evening.

If you use TRUSOPT with another eye drop, the drops should be instilled with a minimum time interval of 10 minutes.

Do not let the tip of the container touch the eyes or the areas surrounding them. It may be contaminated with bacteria that can cause eye infections leading to serious damage to the eyes, including loss of vision. To avoid possible contamination of the container, wash your hands before using this medicine and avoid touching the tip of the container to any surface. If you think your medicine may be contaminated, or if you develop an eye infection, consult your doctor immediately if you can continue using this container.

Instructions for use

Do not use the container if the plastic safety strip around the neck of the container is missing or broken. When you open the container for the first time, tear off the plastic safety strip.

Each time you use TRUSOPT:

  1. Wash your hands.
  1. Open the container. Be careful not to let the tip of the dropper touch your eye, the skin around your eye, or your fingers.

Hand holding a dropper bottle over the eye of a person with their head tilted back

  1. Tilt your head back and hold the container upside down over your eye.

Person tilting their head back while a hand holds a dropper bottle applying drops to the open eye

  1. Pull the lower eyelid down and look up. Hold the container by the flat sides and gently squeeze it to release one drop into the space between the lower eyelid and the eye.
  2. Close your eye and press the inner corner of your eye with your finger for about two minutes. This helps prevent the medicine from reaching the rest of your body.
  3. Repeat steps 3 to 5 with the other eye, if your doctor has told you to do so.
  4. Replace the cap and close the container tightly.

Hands holding a nasal inhaler applying the medication to a patient's nostril in profile

If you use more TRUSOPT than you should

If you put too many drops in your eye or swallow some of the contents of the container, you should tell your doctor immediately.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone (91) 562 04 20, stating the medicine and the amount taken.

If you forget to use TRUSOPT

It is important to use this medicine as your doctor has told you. If you forget to use a dose, use it as soon as you remember. However, if it is almost time for your next dose, do not use the missed dose. Continue with your normal dosing schedule.

Do not use a double dose to make up for forgotten doses.

If you stop using TRUSOPT

If you want to stop using this medicine, consult your doctor first. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If you develop allergic reactions such as hives, swelling of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing, stop using this medicine and consult your doctor immediately.

The following side effects have been reported with TRUSOPT during clinical trials or after marketing:

Very common side effects:(may affect more than 1 in 10 people)

Burning and stinging of the eyes.

Common side effects:(may affect up to 1 in 10 people)

Corneal disease with eye pain and blurred vision (superficial punctate keratitis), discharge with itching of the eyes (conjunctivitis), irritation/inflammation of the eyelid, blurred vision, headache, nausea, bitter taste, and fatigue.

Uncommon side effects:(may affect up to 1 in 100 people)

Inflammation of the iris.

Rare side effects:(may affect up to 1 in 1,000 people)

Numbness or tingling of the hands or feet, transient myopia that resolves when therapy is stopped, development of fluid under the retina (choroidal detachment, after filtration surgery), eye pain, crusts on the eyelid, low eye pressure, inflammation of the cornea (with symptoms of visual disturbances), eye irritation including redness, kidney stones, dizziness, nosebleeds, throat irritation, dry mouth, localized skin rash (contact dermatitis), severe skin reactions, allergic reactions such as skin rash, hives, itching, and in rare cases swelling of the lips, eyes, and mouth, shortness of breath, and more rarely difficulty breathing.

Frequency not known:(cannot be estimated from the available data)

Difficulty breathing, feeling of a foreign body in the eye (feeling of having something in the eye), strong and/or irregular heartbeats (palpitations), increased heart rate, and increased blood pressure.

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Spanish Medicines Agency's website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of TRUSOPT

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label of the container and the carton after 'EXP'. The expiry date is the last day of the month stated.

TRUSOPT should be used within 28 days of opening the container.

This medicine does not require any special storage conditions. Keep the container in the outer carton to protect it from light.

Medicines should not be disposed of via wastewater or household waste. Return the containers and any unused medicine to a pharmacy for disposal. If you are unsure, ask your pharmacist how to dispose of the containers and any unused medicine. This will help protect the environment.

6. Contents of the pack and further information

Composition of TRUSOPT

  • The active substance is dorzolamida.
  • Each ml contains 22.26 mg of dorzolamida hydrochloride equivalent to 20 mg of dorzolamida.
  • The other ingredients are hydroxyethylcellulose, mannitol, sodium citrate, sodium hydroxide, and water for injections. Benzalkonium chloride is added as a preservative.

Appearance and packaging of the product

TRUSOPT is a clear, colourless to almost colourless, slightly viscous solution.

TRUSOPT is available in a 5 ml solution in a white translucent container. The plastic container is closed with a white screw cap.

The safety strip on the label of the container provides evidence that the medicine has not been tampered with.

Container sizes:

1 x 5 ml (one 5 ml container)

3 x 5 ml (three 5 ml containers)

6 x 5 ml (six 5 ml containers)

Not all container sizes may be marketed.

Marketing authorisation holder and manufacturer

Marketing authorisation holder

Santen Oy

Niittyhaankatu 20

33720 Tampere

Finland

Manufacturer

Santen Oy

Kelloportinkatu 1

33100 Tampere

Finland

Local representative

Santen Pharmaceutical Spain S.L.

Acanto, 22, 7º

28045 – Madrid

This medicine is authorised in the Member States of the European Economic Area under the following names:

Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Portugal, Spain, and Sweden:

TRUSOPT

Date of last revision of this leaflet:06/2023

Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/

Online doctors for TRUSOPT 20 mg/ml EYE DROPS SOLUTION

Discuss questions about TRUSOPT 20 mg/ml EYE DROPS SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for TRUSOPT 20 mg/ml EYE DROPS SOLUTION?
TRUSOPT 20 mg/ml EYE DROPS SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in TRUSOPT 20 mg/ml EYE DROPS SOLUTION?
The active ingredient in TRUSOPT 20 mg/ml EYE DROPS SOLUTION is dorzolamide. This information helps identify medicines with the same composition but different brand names.
How much does TRUSOPT 20 mg/ml EYE DROPS SOLUTION cost in pharmacies?
The average pharmacy price for TRUSOPT 20 mg/ml EYE DROPS SOLUTION is around 5.12 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures TRUSOPT 20 mg/ml EYE DROPS SOLUTION?
TRUSOPT 20 mg/ml EYE DROPS SOLUTION is manufactured by Santen Oy. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of TRUSOPT 20 mg/ml EYE DROPS SOLUTION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether TRUSOPT 20 mg/ml EYE DROPS SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to TRUSOPT 20 mg/ml EYE DROPS SOLUTION?
Other medicines with the same active substance (dorzolamide) include ARZOLAN 20 mg/ml EYE DROPS SOLUTION, DIMAZ 20 mg/ml EYE DROPS SOLUTION, DORZOLAMIDE ARISTO 20 mg/ml EYE DROPS SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media